Title Rehabilitacija bolesnika oboljelih od ankilozantnog spondilitisa
Title (english) Rehabilitation of patients with ankylosing spondylitis
Author Lidija Hren
Mentor Željko Jeleč (mentor)
Committee member Manuela Filipec (predsjednik povjerenstva)
Committee member Željko Jeleč (član povjerenstva)
Committee member Anica Kuzmić (član povjerenstva)
Granter University North (University centre Varaždin) (Department of Physiotherapy) Koprivnica
Defense date and country 2021-07-15, Croatia
Scientific / art field, discipline and subdiscipline BIOMEDICINE AND HEALTHCARE Clinical Medical Sciences Physical Medicine and Rehabilitation
Abstract Reumatske bolesti su skup različitih bolesti, koje pretežno oštećuju lokomotorni sustav i imaju zajedničke značajke. Reumatske bolesti mogu se podijeliti u četiri velike skupine: upalni reumatizam, degenerativni reumatizam, izvanzglobni reumatizam i metaboličke bolesti kostiju i zglobova. Seronegativni spondiloartritisi su skupina upalnih reumatskih bolesti koje dijele mnogo zajedničkih obilježja (klinička, radiološka i genetska) i imaju sličan patogenetski mehanizam nastanka te način liječenja. Ankilozantni spondilitis, reaktivni artritis, psorijatični artritis, enteropatski artritis te nediferencirani artritis, bolesti su koje pripadaju seronegativnim spondiloartrtisima. Cilj liječenja seronegativnih spondiloatritisa je smanjenje boli i upale s očuvanjem funkcije i sprječavanjem razvoja teških kontraktura i deformiteta. Bol je intenzivna, perzistentna i ograničavajuća. Ankilozantni spondilitis (AS) je sustavna, progresivna te upalna bolest koja je ime dobila po tome što patološki proces izaziva ankilozu odnosno dovodi do gubitka zglobne pokretljivosti zbog sraštavanja kostiju unutar zgloba ili kalcificiranja okolnih ligamenata. Prvi simptomi bolesti javljaju se u dobi od 20. do 40.godine života. Procjenjuje se da oko 80% oboljelih prve simptome dobije prije 30. godine života. Etiologija ankilozantnog spondilitisa nije u potpunosti poznata, no na samu pojavu bolesti mogu utjecati mnogi faktori. Bolest najčešće počinje lagano i postupno, a tegobe se javljaju nakon nekoliko tjedana ili mjeseci. Ankilozantni spondilitis ima dva stadija, predspondilitički i spondilitički. Kako bolest napreduje tako kralješci sraštavaju, što dovodi do ukočenosti kralježnice i invaliditeta. Dijagnoza se postavlja na temelju anamneze, kliničke slike, fizikalnog pregleda, laboratorijskog i radiološkog nalaza. Postoji New York Modificirani kriterij koji pomaže pri dijagnosticiranju. Ankilozantni spondilitis liječi se simptomatski, odnosno cilj je ukloniti bol i upalu, održati funkcionalnost pacijenta. Liječenje obuhvaća farmakološki i nefarmakološki dio, pa čak i kirurški dio. Liječenje treba započeti edukacijom bolesnika. U sklopu rehabilitacije oboljelih provodi se individualna kineziterapija, elektroterapija, balneoterapija, hidroterapija, ultrazvuk i dijatermija. Dugoročne posljedice za ljude oboljele od ankilozantnog spondilitisa mogu varirati i teško ih je predvidjeti
Abstract (english) Rheumatic diseases are a group of different illnesses that mainly damage the locomotive system and share characteristics. Rheumatic diseases can be divided into four big groups: inflammatory rheumatism, degenerative rheumatism, extraarticular rheumatism, and bone and joint metabolic illnesses. Seronegative spondyloarthritis is a group of inflammatory rheumatic diseases which are divided into groups which share a lot of characteristics (clinical, radiological and genetical) and have similar pathogenic mechanisms of creation, therefore a similar way of treatment. Ankylosing spondylitis, reactive arthritis, psoriatic arthritis, enteropathic arthritis and nondifferential arthritis are diseases that belong to seronegative spondyloarthritis. The goal of treating seronegative spondyloarthritis is reducing pain and inflammation with emphasis on preservation of function and stopping the development of serious contractures and deformities. The pain is intense, persistent and limiting. Ankylosing spondylitis is a systematic, progressive and inflammatory disease, which got its name because the pathological process evokes ankylosis, it leads to loss of joint mobility because of bone scaring inside a joint or calcification of surrounding ligaments. The first symptoms of illness occur in the age range of 20 to 40 years old. It is estimated that 80% of effected people experienced the first symptoms before the age of 30. Ethology is not entirely known, but there are many different factors that can influence the occurrence of the illness. The disease usually starts slowly and gradually, symptoms occur within a few weeks or months. Ankylosing spondylitis has two stages. As the disease progresses, the vertebrae fuse, which leads to stiffness of the spine and can lead to a disability. The diagnosis is established on the foundation of anamnesis, clinical picture, physical examination, laboratory and radiological findings. The New York diagnostic criteria helps determine a diagnosis. Ankylosing spondylitis is treated symptomatically; the goal is to diminish pain and inflammation and preserve the functionality of a patient. Treatment includes pharmacological and non-pharmacological part and can even lead to surgery. The treatment needs to start by educating the patient. Rehabilitation includes individual kinesitherapy, electrotherapy, balneotherapy, hydrotherapy, ultrasound and diathermy. Long-term consequences for people suffering from ankylosing spondylitis can vary and are hard to predict.
Keywords
ankilozantni spondilitis
HLA B-27
biološki lijek
edukacija
rehabilitacija
fizioterapija
Keywords (english)
ankylosing spondylitis
HLA B-27
biological medicine
rehabilitation
physiotherapy
Language croatian
URN:NBN urn:nbn:hr:122:181670
Study programme Title: physiotherapy Study programme type: professional Study level: undergraduate Academic / professional title: stručni/a prvostupnik/ prvostupnica (baccalaureus/ baccalaurea) fizioterapije (stručni/a prvostupnik/ prvostupnica (baccalaureus/ baccalaurea) fizioterapije)
Type of resource Text
File origin Born digital
Access conditions Open access
Terms of use
Created on 2021-07-22 10:02:37